A survey on managing multiple sclerosis the managed care perspective

P and T

Volumn 36, Issue 6, 2011, Pages 374-375

  Edlin, Mari ^a   Sonnenreich, Peter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPYRA; BETA1A INTERFERON; CLADRIBINE; DALFAMPRIDINE; FINGOLIMOD; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; NATALIZUMAB; UNCLASSIFIED DRUG;

ARTICLE; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE UTILIZATION; HEALTH MAINTENANCE ORGANIZATION; HEALTH SURVEY; HUMAN; MANAGED CARE; MANAGED CARE ORGANIZATION; MULTIPLE SCLEROSIS; PHARMACY; RISK BENEFIT ANALYSIS;

EID: 79959984462     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. The Multiple Sclerosis Trend Report: Perspectives From Managed Care, Providers and Employers, 2nd ed. Teva/National Multiple Sclerosis Society, 2011.
2. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: A cross-sectional study in the United States. Neurology 2006;66(11):1696-1702. Available at: www.ncbi.nlm.nih.gov/pubmed/16769943